Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor approved for 200 mg twice-daily dosing in conjunction with other antiretrovirals (ARVs), has pharmacokinetic properties which support once-daily dosing.
Methods
In this single-arm, open-label study, 79 treatment-naive HIV-infected adults were assigned to receive ETR 400 mg plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) 300/200 mg once daily to assess antiviral activity, safety and tolerability. ARV activity at 48 weeks was determined by proportion of subjects with HIV-1 RNA<50 copies/ml (intention-to-treat, missing = failure).
Results
Of 79 eligible subjects, 90% were men, 62% African-American and 29% Caucasian. At baseline, median (Q1, Q3) age was 29 years (23, 44) and HIV-1 RNA 4.52 log10 copies/ml (4.07, 5.04). A total of 69 (87%) completed a week 48 visit and 61 (77%, 95% CI 66%, 86%) achieved HIV-1 RNA<50 copies/ml at week 48. At time of virological failure, genotypic resistance-associated mutations were detected in three participants, two with E138K (one alone and one with additional mutations). Median (95% CI) CD4+ cell count increase was 163 (136, 203) cells/μl. Fifteen (19.0%) participants reported a new sign/symptom or lab abnormality ≥ Grade 3 and three participants (3.8%) permanently discontinued ETR due to toxicity. Two participants had psychiatric symptoms of any grade. There were no deaths.
Conclusions
In this study of ARV-naive HIV-positive adults, once-daily ETR with TDF/FTC had acceptable antiviral activity and was well-tolerated. Once-daily ETR may be a plausible option as part of a combination ARV regimen for treatment-naive individuals. ClinicalTrials.gov NCT00959894.
References
1.
KatlamaC., ClotetB., MillsA.Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.Antivir Ther2010; 15: 1045–1052.
2.
Schöller-GyüreM., KakudaT.N., De SmedtG.Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1 negative volunteers.47th Interscience Conference of Antimicrobial Agents and Chemotherapy. 17 September 2007, Chicago, IL, USA.
3.
Di PerriG., GreenB., MorrishG.Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naive patients.HIV Clin Trials2013; 14: 92–98.
4.
GazzardB., DuvivierC., ZaglerC.Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.AIDS2011; 25: 2249–2258.
5.
MadrugaJ.V., CahnP., GrinsztejnB.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.Lancet2007; 370: 29–38.
6.
LazzarinA., CampbellT., ClotetB.Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.Lancet2007; 370: 39–48.
7.
GirardP.M., CampbellT.B., GrinsztejnB.Pooled week 96 results of the Phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.HIV Med2012; 13: 427–435.
8.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA2004; 292: 191–201.
9.
ChesneyM.A., IckovicsJ.R., ChambersD.B.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).AIDS Care2000; 12: 255–266.
10.
MatthewsD.R., HoskerJ.P., RudenskiA.S., NaylorB.A., TreacherD.F., TurnerR.C.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia1985; 28: 412–419.
11.
TambuyzerL., VingerhoetsJ., AzijnH.Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.AIDS Res Hum Retroviruses2010; 26: 1197–1205.
12.
RimskyL., VingerhoetsJ., Van EygenV.Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis.J Acquir Immune Defic Syndr2012; 59: 39–46.
13.
MolinaJ.M., CahnP., GrinsztejnB.Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial.Lancet2011; 378: 238–246.
14.
KimE.Y., Lorenzo-RedondoR., LittleS.J.Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.PLoS Pathog2014; 10: e1004281.
15.
FouratiS., MaletI., LambertS.E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.AIDS2012; 26: 1619–1624.
16.
McCallumM., OliveiraM., IbanescuR.I.Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.Antimicrob Agents Chemother2013; 57: 4681–4688.
17.
XuH.T., Colby-GerminarioS.P., AsahchopE.L.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Antimicrob Agents Chemother2013; 57: 3100–3109.
18.
HuZ., KuritzkesD.R.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.J Virol2011; 85: 11309–11314.
19.
EcheverríaP., BonjochA., PuigJ.Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.PLoS ONE2014; 9: e84676.
20.
CasadoJ.L., de Los SantosI., Del PalacioM.Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.HIV Clin Trials2013; 14: 1–9.
21.
WatersL., FisherM., WinstonA.A Phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.AIDS2011; 25: 65–71.
22.
MonteiroP., PerezI., LagunoM.Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.J Antimicrob Chemother2014; 69: 742–748.
23.
NelsonM., HillA., van DelftY., MoecklinghoffC.Etravirine as a switching option for patients with HIV RNA suppression: a review of recent trials.AIDS Res Treat2014; 2014: 636584.
24.
van LethF., PhanuphakP., StroesE.Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.PLoS Med2004; 1: e19.
25.
FisacC., FumeroE., CrespoM.Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.AIDS2005; 19: 917–925.
26.
NegredoE., RibaltaJ., FerreR.Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.AIDS2004; 18: 819–821.
27.
Floris-MooreM.M.K., WilkinA.M., JohnsonM.Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults.IDWeek™ 2013, Joint Meeting of the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America, San Francisco, 2 October 2013, CA, USA.
